Altimmune (ALT) EBT (2010 - 2026)
Altimmune (ALT) reported EBT of -$22.6 million for Q1 2026, down 11.39% year-over-year from -$25.5 million in Q1 2025, and down 138.98% on a QoQ basis from $57.9 million in Q4 2025.
Altimmune (ALT) has 17 years of EBT data on file, last reported at -$22.6 million in Q1 2026.
- Quarterly EBT fell 11.39% year-over-year to -$22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.8 million (up 93.58% YoY) and the FY2025 annual result came in at -$3.5 million, up 96.29% from the prior year.
- EBT retreated to -$22.6 million in Q1 2026 per ALT's latest filing, from $57.9 million in the prior quarter.
- Across five years, EBT topped out at $57.9 million in Q4 2025 and bottomed at -$24.6 million in Q2 2024.
- The 5-year median for EBT is -$20.3 million (2025), against an average of -$11.7 million.
- The widest annual swing landed in 2022, when EBT soared 1049.28%; it then sank 160.71% in 2024.
- Tracing ALT's EBT over 5 years: stood at $51.1 million in 2022, then plunged by 117.4% to -$8.9 million in 2023, then tumbled by 160.71% to -$23.2 million in 2024, then surged by 349.74% to $57.9 million in 2025, then plunged by 138.98% to -$22.6 million in 2026.
- Per Business Quant, the three latest ALT EBT figures stand at -$22.6 million (Q1 2026), $57.9 million (Q4 2025), and -$19.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | -22.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | 57.89 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -20.26 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -8.89 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.17 Mn |
| Mar 31, 2023 | -20.09 Mn |
| Dec 31, 2022 | 51.09 Mn |
| Sep 30, 2022 | -23.71 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.54 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |
| Mar 31, 2021 | -14.86 Mn |
| Dec 31, 2020 | -10.73 Mn |
| Sep 30, 2020 | -18.25 Mn |
| Jun 30, 2020 | -18.35 Mn |
| Mar 31, 2020 | -7.13 Mn |
| Dec 31, 2019 | -4.10 Mn |
| Sep 30, 2019 | -11.00 Mn |
| Jun 30, 2019 | -3.39 Mn |
| Mar 31, 2019 | -2.10 Mn |
| Dec 31, 2018 | -27.34 Mn |
| Sep 30, 2018 | -3.18 Mn |
| Jun 30, 2018 | -10.64 Mn |
| Mar 31, 2018 | -4.17 Mn |
| Dec 31, 2017 | -11.94 Mn |
| Sep 30, 2017 | -31.44 Mn |
| Jun 30, 2017 | -4.10 Mn |
| Mar 31, 2017 | -4.58 Mn |
| Dec 31, 2016 | -3.06 Mn |
| Sep 30, 2016 | -4.80 Mn |
| Jun 30, 2016 | -1.62 Mn |
| Mar 31, 2016 | -1.21 Mn |
| Dec 31, 2015 | -1.22 Mn |
| Sep 30, 2015 | -1.31 Mn |
| Jun 30, 2015 | -2.33 Mn |
| Mar 31, 2015 | 1.48 Mn |
| Dec 31, 2014 | -2.62 Mn |
| Sep 30, 2014 | -4.60 Mn |
| Jun 30, 2014 | -445,788.00 |
| Mar 31, 2014 | -2.23 Mn |
| Dec 31, 2013 | -4.41 Mn |
| Sep 30, 2013 | -3.92 Mn |
| Jun 30, 2013 | -1.23 Mn |
| Mar 31, 2013 | -2.10 Mn |
| Dec 31, 2012 | -1.26 Mn |
| Sep 30, 2012 | -191,864.00 |
| Jun 30, 2012 | -740,410.00 |
| Mar 31, 2012 | -2.53 Mn |
| Dec 31, 2011 | 749,193.00 |
| Sep 30, 2011 | -33,496.00 |
| Jun 30, 2011 | -2.44 Mn |
| Mar 31, 2011 | -2.08 Mn |
| Dec 31, 2010 | -10.37 Mn |
| Sep 30, 2010 | -4.31 Mn |
| Jun 30, 2010 | -6.46 Mn |